Cover Image
市場調查報告書

全身性紅斑性狼瘡的治療藥:全球市場

Drugs for Treating Systemic Lupus Erythematosus: Global Markets

出版商 BCC Research 商品編碼 298486
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
Back to Top
全身性紅斑性狼瘡的治療藥:全球市場 Drugs for Treating Systemic Lupus Erythematosus: Global Markets
出版日期: 2014年03月28日 內容資訊: 英文 129 Pages
簡介

全身性紅斑性狼瘡(SLE)是症狀嚴重的慢性自我免疫疾病。到目前為止所認可的市場銷售治療藥較少、對於未應對的醫療需求來說是重要的存在領域、目前很多企業持續開發新的治療藥。依此、全球市場的治療藥銷售額從2013年的9億5,020萬美金到2018年預計會提升到26億美金、這之間的年平均成長率為22.4%。

本報告書為使用SLE治療的醫藥品及治療法的全球市場之概觀、分析市場的發展趨勢、以及到2018年為止的展望、業界的結構及各國政府的規範、現在開發推動中的技術等今後的需求影響之因素及各企業開發中的產品生產線之相關分析外、還有主要廠商的介紹、概述如下。

第1章 介紹

第2章 實施摘要

第3章 概要

  • 症兆和症狀
  • 紅斑性狼瘡的種類
    • 全身性紅斑性狼瘡(SLE)
    • 皮膚紅斑性狼瘡(CLE)
    • 藥劑誘發性狼瘡
    • 新生兒紅斑性狼瘡
  • 病態生理學
    • 疾病的定義
    • 臨床症狀
  • 進行和重症度
  • 病因
    • 遺傳學的因素
    • 環境的因素
    • 賀爾蒙的因素
  • 疫學和患者數
    • 美國
    • 法國
    • 德國
    • 英國
    • 西班牙
    • 義大利
    • 日本
  • 全身性紅斑性狼瘡和所診斷的藥物治療接受人數

第4章 現在的醫療和市場概況

  • 診斷檢查和一般的認知度
    • 主要診斷檢查
  • 臨床勸告和診斷演算法
  • 鑑別診斷
  • 介紹模式
    • 美國
    • 法國
    • 德國
    • 英國
    • 西班牙
    • 義大利
    • 日本

第5章 現在的治療法

  • 抗瘧疾藥
  • 非類固醇抗炎藥(NSAIDS)
  • 副腎皮質類固醇
  • 細胞毒性藥及免疫抑製藥
    • Cyclophosphamide
    • Mycophenolate Mofetil
    • 甲氨蝶呤
    • Cyclosporine
    • Tacrolimus
  • 生物製劑
    • B細胞標的治療
    • BLyS阻礙劑(belimumab)
  • SLE的治療藥所認定的生物製劑
    • belimumab
  • 承認適應症外使用的生物製劑
    • 抗CD20抗體:Rituximab
  • 小分子化合物

第6章 未應對的需求

  • 效能和安全性
  • 動脈粥狀硬化預防的必要性
  • 類固醇使用的頻率和減少期間的類固醇節減療法
  • 每個患者的特別治療法
  • 神經認知功能障礙的預防
  • 骨質疏鬆症和骨質壞死的預防
  • 早期診斷

第7章 新的治療法

  • 醫藥品開發和規範面的課題
  • 新的治療法
  • B細胞調節器
  • T細胞調節器
  • 免疫抑製藥和細胞毒性藥
  • 炎症性細胞激素阻礙劑

第8章 市場的展望

  • 美國
  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 日本

第9章 專利

第10章 主要企業的介紹

  • ANTHERA PHARMACEUTICALS INC
  • BIOTEST AG
  • BIOTICA TECHNOLOGY LTD.
  • CEPHALON
  • CORNERSTONE THERAPEUTICS INC.
  • CREABILIS THERAPEUTICS S.R.L.
  • DYNAVAX TECHNOLOGIES
  • ELI LILLY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE PLC (GSK)
  • HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
  • HANSA MEDICAL AB
  • HARBOR BIOSCIENCES
  • IMMUNOMEDICS, INC.
  • IDERA PHARMACEUTICALS INC.
  • IMMUPHARMA PLC
  • JOHNSON & JOHNSON LTD.
  • ISOTECHNIKA PHARMA INC
  • KINETA INC.
  • Kyorin製藥
  • LYCERA CORPORATION
  • MERCK KGAA
  • MACROGENICS, INC.
  • NOVO NORDISK
  • NEOVACS S.A.
  • NASVAX LTD.
  • ONYX PHARMACEUTICALS INC.
  • PHARMACYCLIS
  • PORTOLA PHARMACEUTICALS INC.
  • PFIZER LIMITED
  • REVO BIOLOGICS
  • RIGEL PHARMACEUTICALS INC
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • UCB GROUP/ IMMUNOMEDICS
  • VACCINEX INC.

圖表清冊

目錄
Product Code: PHM159A

The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to reach $950.2 million in 2013 and $2.6 billion in 2018, a compound annual growth rate (CAGR) of 22.4%.

This report provides:

  • An overview of the global market for drugs and therapeutics used to treat systemic lupus erythematosus (SLE)
  • Analyses of global market trends, with data from 2013 and projections of CAGRs through 2018.
  • Analyses of factors influencing market demand such as the industry's structure, governmental regulations, and developing technologies
  • Details concerning the developmental product pipeline for therapeutics uesd to treat SLE
  • Profiles of leading companies in the industry.

STUDY GOALS AND OBJECTIVES

BCC Research's goal in conducting this study was to determine the current status of systemic lupus erythematosus (SLE) disease treatments and assess the growth potential of this area over a five-year period, from 2013 to 2018. Our key objective was to present a comprehensive analysis of the current pipeline of therapeutics, analyze the market and forecast for SLE therapeutics along with outlining the key factors that will influence this therapeutic area in the next few years.

REASONS FOR DOING THIS STUDY

SLE is a devastating and chronic autoimmune disorder affecting almost all the organs, with only one approved marketed drug- making this a significant area of unmet medical need. But there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in SLE drugs.

SCOPE OF REPORT

The scope of this report focuses on the pharmaceutical segment. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the market segment's economic environment, market factors and potential, and forecasts for 2013 to 2018. This study will be of interest to the drug industry, patients and the medical community. It will also be of interest to suppliers of products and services to this market area.

ANALYST'S CREDENTIALS

Dr. Sanjukta Bhattacharyya is the BCC Research analyst of this report. She holds a PhD in endocrinology from the University of Calcutta in India, and has more than 14 years of experience in the pharmaceutical industry, having been associated with leading pharmaceutical companies in clinical research and project management. Of note was the successful clinical development of an antimalarial new chemical entity (NCE) (Synriam), leading to its regulatory submission and transitioning to market. Synriam became the first new drug by an Indian pharmaceutical company. Sanjukta has played significant roles in various licensing deals and alliance management for NCE codevelopment between partners. Skilled in ICH/GCP guidelines and protocols, and experienced in conducting clinical trials, Sanjukta also does medical writing involving the preparation of clinical study protocols, various relevant documents, and study reports. She also has several publications in peer-reviewed journals.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE A: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018 (MILLIONS)
  • SUMMARY FIGURE A: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018 (%)
  • SUMMARY TABLE B: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE B: GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (%)
    • KEY FACTORS DRIVING THE MARKET
    • KEY FACTORS RESTRICTING THE MARKET
    • NOTABLE PIPELINE ACTIVITIES
    • KEY CHALLENGES IN THE MARKET FOR SLE THERAPIES
    • KEY OPPORTUNITIES IN THE MARKET FOR SLE THERAPIES
  • SUMMARY TABLE C SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018

CHAPTER 3 - OVERVIEW

  • SIGNS AND SYMPTOMS
  • TYPES OF LUPUS
    • SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    • CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
    • DRUG-INDUCED LUPUS
    • NEONATAL LUPUS ERYTHEMATOSUS
  • PATHOPHYSIOLOGY
    • DISEASE DEFINITION
    • CLINICAL MANIFESTATIONS
      • TABLE 1: PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE
      • TABLE 2: DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS
      • TABLE 3: CLASSIFICATION OF LUPUS NEPHRITIS
      • TABLE 4: WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS
  • PROGRESSION AND SEVERITY
  • ETIOLOGY
    • GENETIC FACTORS
    • ENVIRONMENTAL FACTORS
      • Ultraviolet Light:
    • HORMONAL FACTORS
  • EPIDEMIOLOGY AND PATIENT POPULATIONS
    • U.S.
    • FRANCE
    • GERMANY
    • U.K.
    • SPAIN
    • ITALY
    • JAPAN
  • DIAGNOSED AND DRUG TREATED POPULATION
    • TABLE 5: DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION

CHAPTER 4 - CURRENT MEDICAL PRACTICE AND MARKET PROFILES

  • DIAGNOSIS SCREENING AND PUBLIC AWARENESS
    • KEY DIAGNOSTIC TESTS
      • Serologic Tests
        • Anti-nuclear Antibody (ANA)
        • Antibodies to Extractable Nuclear Antigens (ENAs)
        • Prognostic Markers and the Role of Autoantibodies
  • CLINICAL RECOMMENDATIONS AND DIAGNOSIS ALGORITHM
    • FIGURE 1: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
  • DIFFERENTIAL DIAGNOSIS
    • TABLE 6: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS
    • FIGURE 2: PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 3: TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    • TABLE 7: TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS
  • REFERRAL PATTERNS
    • U.S.
    • FRANCE
    • GERMANY
    • U.K.
    • SPAIN
    • ITALY
    • JAPAN

CHAPTER 5 - CURRENT THERAPIES

  • TABLE 8: CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM
  • ANTIMALARIAL DRUGS
  • NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  • CORTICOSTEROIDS
  • CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS
    • CYCLOPHOSPHAMIDE
      • Azathioprine
    • MYCOPHENOLATE MOFETIL
    • METHOTREXATE
    • CYCLOSPORINE
    • TACROLIMUS
  • BIOLOGICS
    • B-CELL TARGETED THERAPY
    • BLYS-BLOCKERS (BELIMUMAB)
  • BIOLOGICS APPROVED FOR TREATING SLE
    • BELIMUMAB
      • TABLE 9: BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)
      • TABLE 10: ENDPOINTS USED IN CLINICAL TRIALS FOR SLE
  • BIOLOGICS USED OFF-LABEL
    • ANTI-CD20 ANTIBODY: RITUXIMAB (RITUXAN/MABTHERA; BIOGEN IDEC/ROCHE/ZENYAKU KOGYO)
  • SMALL MOLECULES
    • TABLE 11: CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED
    • TABLE 12: TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY
    • TABLE 13: STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY

CHAPTER 6 - UNMET NEEDS

  • EFFICACY AND SAFETY
  • NEED FOR PREVENTION OF ATHEROSCLEROSIS
  • STEROID SPARING THERAPY TO REDUCE THE DOSE AND DURATION OF STEROID USE
  • THERAPIES TAILORED TO INDIVIDUAL PATIENTS
  • PREVENTION OF NEUROCOGNITIVE DYSFUNCTION
  • PREVENTION OF OSTEOPOROSIS AND OSTEONECROSIS
  • EARLY DIAGNOSIS

CHAPTER 7 - EMERGING THERAPIES

  • DRUG DEVELOPMENT AND REGULATORY CHALLENGES
  • EMERGING THERAPIES
  • B-CELL MODULATORS
    • BELIMUMAB
    • ATACICEPT
    • EPRATUZUMAB
    • TABALUMAB:
    • RIGERIMOD
    • BLISIBIMOD
  • T-CELL MODULATORS
  • IMMUNOSUPPRESSIVE AND CYTOTOXIC DRUGS
  • PROINFLAMMATORY AND CYTOKINE INHIBITORS
    • ANTI-IFN-A/γ
      • TABLE 14: EMERGING THERAPIES BY PHASES OF DEVELOPMENT
      • TABLE 15: NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT
      • FIGURE 4: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE
      • TABLE 16: POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE

CHAPTER 8 - MARKET OUTLOOK

  • TABLE 17: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
  • TABLE 18: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018 ($ MILLIONS)
  • TABLE 19: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
  • FIGURE 5: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
  • UNITED STATES
    • TABLE 20: U.S.- SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
    • FIGURE 6: U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • FRANCE
    • TABLE 21: FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 7: FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • GERMANY
    • TABLE 22: GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 8: GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • U.K.
    • TABLE 23: U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 9: U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • SPAIN
    • TABLE 24: SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 10: SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • ITALY
    • TABLE 25: ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 11: ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • JAPAN
    • TABLE 26: JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 12: JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • TABLE 27: SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 28: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018 ($ MILLIONS)
    • TABLE 29: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018 ($ MILLIONS)
    • TABLE 30: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY,THROUGH 2018 ($ MILLIONS)
    • TABLE 31: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018 ($ MILLIONS)
    • TABLE 32: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018 ($ MILLIONS)

CHAPTER 9 - PATENTS

  • TABLE 35: NO. OF PATENTS
  • TABLE 36: ISSUED PATENTS
  • TABLE 37: PATENT APPLICATIONS

CHAPTER 10 - COMPANY PROFILES

  • ANTHERA PHARMACEUTICALS INC
  • BIOTEST AG
  • BIOTICA TECHNOLOGY LTD.
  • CEPHALON
  • CORNERSTONE THERAPEUTICS INC.
  • CREABILIS THERAPEUTICS S.R.L.
  • DYNAVAX TECHNOLOGIES
  • ELI LILLY
  • F. HOFFMANN-LA ROCHE LTD
    • EVENTS OF 2013 AND 2014
  • GLAXOSMITHKLINE PLC (GSK)
  • HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
  • HANSA MEDICAL AB
  • HARBOR BIOSCIENCES
  • IMMUNOMEDICS, INC.
  • IDERA PHARMACEUTICALS INC.
  • IMMUPHARMA PLC
  • JOHNSON & JOHNSON LTD.
  • ISOTECHNIKA PHARMA INC
  • KINETA INC.
  • KYORIN PHARMACEUTICALS CO. LTD
  • LYCERA CORPORATION
  • MERCK KGAA
  • MACROGENICS, INC.
  • NOVO NORDISK
  • NEOVACS S.A.
  • NASVAX LTD.
  • ONYX PHARMACEUTICALS INC.
  • PHARMACYCLIS
  • PORTOLA PHARMACEUTICALS INC.
  • PFIZER LIMITED
  • REVO BIOLOGICS
  • RIGEL PHARMACEUTICALS INC
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • UCB GROUP/ IMMUNOMEDICS
  • VACCINEX INC.

LIST OF TABLES

  • SUMMARY TABLE A: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018 (MILLIONS)
  • SUMMARY TABLE B: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY TABLE C: SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018
    • TABLE 1: PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE
    • TABLE 2: DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS
    • TABLE 3: CLASSIFICATION OF LUPUS NEPHRITIS
    • TABLE 4: WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS
    • TABLE 5: DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION
    • TABLE 6: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS
    • TABLE 7: TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS
    • TABLE 8: CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM
    • TABLE 9: BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)
    • TABLE 10: ENDPOINTS USED IN CLINICAL TRIALS FOR SLE
    • TABLE 11: CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED
    • TABLE 12: TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY
    • TABLE 13: STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY
    • TABLE 14: EMERGING THERAPIES BY PHASES OF DEVELOPMENT
    • TABLE 15: NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT
    • TABLE 16: POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE
    • TABLE 17: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
    • TABLE 18: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018 ($ MILLIONS)
    • TABLE 19: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 20: U.S.- SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
    • TABLE 21: FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 22: GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 23: U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 24: SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 25: ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 26: JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 27: SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 28: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018 ($ MILLIONS)
    • TABLE 29: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018 ($ MILLIONS)
    • TABLE 30: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY,THROUGH 2018 ($ MILLIONS)
    • TABLE 31: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018 ($ MILLIONS)
    • TABLE 32: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018 ($ MILLIONS)
    • TABLE 35: NO. OF PATENTS
    • TABLE 36: ISSUED PATENTS
    • TABLE 37: PATENT APPLICATIONS

LIST OF FIGURES

  • SUMMARY FIGURE A GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018 (%)
  • SUMMARY FIGURE B GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (%)
    • FIGURE 1: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 2: PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 3: TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 4: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE
    • FIGURE 5: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
    • FIGURE 6: U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 7: FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 8: GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 9: U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 10: SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 11: ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 12: JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
Back to Top